nodes	percent_of_prediction	percent_of_DWPC	metapath
Halofantrine—CYP3A4—bone cancer	0.928	1	CbGaD
Halofantrine—Lumefantrine—CYP3A4—bone cancer	0.0099	1	CrCbGaD
Halofantrine—Haemolysis—Cisplatin—bone cancer	0.00399	0.0715	CcSEcCtD
Halofantrine—Tetany—Cisplatin—bone cancer	0.00389	0.0698	CcSEcCtD
Halofantrine—Haematocrit decreased—Methotrexate—bone cancer	0.00187	0.0335	CcSEcCtD
Halofantrine—Haemolytic anaemia—Cisplatin—bone cancer	0.00102	0.0183	CcSEcCtD
Halofantrine—Cerebrovascular accident—Cisplatin—bone cancer	0.000939	0.0169	CcSEcCtD
Halofantrine—Face oedema—Cisplatin—bone cancer	0.000888	0.0159	CcSEcCtD
Halofantrine—KCNH2—Hematopoietic Stem Cell Differentiation—FLI1—bone cancer	0.000877	0.129	CbGpPWpGaD
Halofantrine—Orthostatic hypotension—Cisplatin—bone cancer	0.00084	0.0151	CcSEcCtD
Halofantrine—Rigors—Epirubicin—bone cancer	0.000797	0.0143	CcSEcCtD
Halofantrine—Rigors—Doxorubicin—bone cancer	0.000738	0.0132	CcSEcCtD
Halofantrine—Stomatitis—Cisplatin—bone cancer	0.000691	0.0124	CcSEcCtD
Halofantrine—Depressed level of consciousness—Methotrexate—bone cancer	0.000672	0.0121	CcSEcCtD
Halofantrine—Pulmonary oedema—Methotrexate—bone cancer	0.000619	0.0111	CcSEcCtD
Halofantrine—Visual impairment—Cisplatin—bone cancer	0.000613	0.011	CcSEcCtD
Halofantrine—Tinnitus—Cisplatin—bone cancer	0.000593	0.0107	CcSEcCtD
Halofantrine—Pulmonary oedema—Epirubicin—bone cancer	0.000579	0.0104	CcSEcCtD
Halofantrine—Arrhythmia—Cisplatin—bone cancer	0.000569	0.0102	CcSEcCtD
Halofantrine—Abnormal vision—Epirubicin—bone cancer	0.000568	0.0102	CcSEcCtD
Halofantrine—Pulmonary oedema—Doxorubicin—bone cancer	0.000536	0.00962	CcSEcCtD
Halofantrine—Abnormal vision—Doxorubicin—bone cancer	0.000525	0.00943	CcSEcCtD
Halofantrine—Cerebrovascular accident—Methotrexate—bone cancer	0.000515	0.00925	CcSEcCtD
Halofantrine—Ill-defined disorder—Cisplatin—bone cancer	0.000514	0.00923	CcSEcCtD
Halofantrine—Malaise—Cisplatin—bone cancer	0.0005	0.00897	CcSEcCtD
Halofantrine—Cerebrovascular accident—Epirubicin—bone cancer	0.000482	0.00865	CcSEcCtD
Halofantrine—Convulsion—Cisplatin—bone cancer	0.00048	0.00862	CcSEcCtD
Halofantrine—Myalgia—Cisplatin—bone cancer	0.000472	0.00847	CcSEcCtD
Halofantrine—Discomfort—Cisplatin—bone cancer	0.000466	0.00837	CcSEcCtD
Halofantrine—Face oedema—Epirubicin—bone cancer	0.000456	0.00819	CcSEcCtD
Halofantrine—Anaphylactic shock—Cisplatin—bone cancer	0.000452	0.00812	CcSEcCtD
Halofantrine—Cerebrovascular accident—Doxorubicin—bone cancer	0.000446	0.00801	CcSEcCtD
Halofantrine—Orthostatic hypotension—Epirubicin—bone cancer	0.000431	0.00775	CcSEcCtD
Halofantrine—Anorexia—Cisplatin—bone cancer	0.000431	0.00774	CcSEcCtD
Halofantrine—Face oedema—Doxorubicin—bone cancer	0.000422	0.00758	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000412	0.0074	CcSEcCtD
Halofantrine—Abdominal distension—Epirubicin—bone cancer	0.000411	0.00738	CcSEcCtD
Halofantrine—Paraesthesia—Cisplatin—bone cancer	0.000406	0.00729	CcSEcCtD
Halofantrine—Orthostatic hypotension—Doxorubicin—bone cancer	0.000399	0.00717	CcSEcCtD
Halofantrine—Decreased appetite—Cisplatin—bone cancer	0.000393	0.00706	CcSEcCtD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—FEV—bone cancer	0.000389	0.0575	CbGpPWpGaD
Halofantrine—Abdominal distension—Doxorubicin—bone cancer	0.00038	0.00683	CcSEcCtD
Halofantrine—Stomatitis—Methotrexate—bone cancer	0.000379	0.00681	CcSEcCtD
Halofantrine—Pollakiuria—Epirubicin—bone cancer	0.000377	0.00677	CcSEcCtD
Halofantrine—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000373	0.0551	CbGpPWpGaD
Halofantrine—Feeling abnormal—Cisplatin—bone cancer	0.000373	0.00669	CcSEcCtD
Halofantrine—Stomatitis—Epirubicin—bone cancer	0.000355	0.00637	CcSEcCtD
Halofantrine—Pollakiuria—Doxorubicin—bone cancer	0.000349	0.00627	CcSEcCtD
Halofantrine—Visual impairment—Methotrexate—bone cancer	0.000337	0.00604	CcSEcCtD
Halofantrine—Stomatitis—Doxorubicin—bone cancer	0.000328	0.00589	CcSEcCtD
Halofantrine—Tinnitus—Methotrexate—bone cancer	0.000326	0.00585	CcSEcCtD
Halofantrine—Asthenia—Cisplatin—bone cancer	0.000324	0.00582	CcSEcCtD
Halofantrine—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000323	0.0477	CbGpPWpGaD
Halofantrine—Visual impairment—Epirubicin—bone cancer	0.000315	0.00565	CcSEcCtD
Halofantrine—Chills—Methotrexate—bone cancer	0.000313	0.00563	CcSEcCtD
Halofantrine—Diarrhoea—Cisplatin—bone cancer	0.000309	0.00555	CcSEcCtD
Halofantrine—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000309	0.0456	CbGpPWpGaD
Halofantrine—Tinnitus—Epirubicin—bone cancer	0.000305	0.00547	CcSEcCtD
Halofantrine—Back pain—Methotrexate—bone cancer	0.000294	0.00528	CcSEcCtD
Halofantrine—Chills—Epirubicin—bone cancer	0.000293	0.00526	CcSEcCtD
Halofantrine—Arrhythmia—Epirubicin—bone cancer	0.000292	0.00524	CcSEcCtD
Halofantrine—Visual impairment—Doxorubicin—bone cancer	0.000291	0.00523	CcSEcCtD
Halofantrine—Vomiting—Cisplatin—bone cancer	0.000287	0.00516	CcSEcCtD
Halofantrine—Rash—Cisplatin—bone cancer	0.000285	0.00512	CcSEcCtD
Halofantrine—Dermatitis—Cisplatin—bone cancer	0.000285	0.00511	CcSEcCtD
Halofantrine—Ill-defined disorder—Methotrexate—bone cancer	0.000282	0.00506	CcSEcCtD
Halofantrine—Tinnitus—Doxorubicin—bone cancer	0.000282	0.00506	CcSEcCtD
Halofantrine—Back pain—Epirubicin—bone cancer	0.000275	0.00494	CcSEcCtD
Halofantrine—Malaise—Methotrexate—bone cancer	0.000274	0.00492	CcSEcCtD
Halofantrine—Chills—Doxorubicin—bone cancer	0.000271	0.00487	CcSEcCtD
Halofantrine—Arrhythmia—Doxorubicin—bone cancer	0.00027	0.00485	CcSEcCtD
Halofantrine—Nausea—Cisplatin—bone cancer	0.000269	0.00482	CcSEcCtD
Halofantrine—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000266	0.0393	CbGpPWpGaD
Halofantrine—Cough—Methotrexate—bone cancer	0.000265	0.00476	CcSEcCtD
Halofantrine—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000265	0.0391	CbGpPWpGaD
Halofantrine—Ill-defined disorder—Epirubicin—bone cancer	0.000264	0.00474	CcSEcCtD
Halofantrine—Convulsion—Methotrexate—bone cancer	0.000263	0.00473	CcSEcCtD
Halofantrine—Arthralgia—Methotrexate—bone cancer	0.000259	0.00465	CcSEcCtD
Halofantrine—Myalgia—Methotrexate—bone cancer	0.000259	0.00465	CcSEcCtD
Halofantrine—Chest pain—Methotrexate—bone cancer	0.000259	0.00465	CcSEcCtD
Halofantrine—Malaise—Epirubicin—bone cancer	0.000257	0.00461	CcSEcCtD
Halofantrine—Discomfort—Methotrexate—bone cancer	0.000256	0.00459	CcSEcCtD
Halofantrine—Back pain—Doxorubicin—bone cancer	0.000255	0.00457	CcSEcCtD
Halofantrine—Palpitations—Epirubicin—bone cancer	0.000251	0.00451	CcSEcCtD
Halofantrine—Confusional state—Methotrexate—bone cancer	0.00025	0.00449	CcSEcCtD
Halofantrine—Cough—Epirubicin—bone cancer	0.000248	0.00446	CcSEcCtD
Halofantrine—Anaphylactic shock—Methotrexate—bone cancer	0.000248	0.00445	CcSEcCtD
Halofantrine—Convulsion—Epirubicin—bone cancer	0.000247	0.00443	CcSEcCtD
Halofantrine—Ill-defined disorder—Doxorubicin—bone cancer	0.000244	0.00438	CcSEcCtD
Halofantrine—Arthralgia—Epirubicin—bone cancer	0.000242	0.00435	CcSEcCtD
Halofantrine—Myalgia—Epirubicin—bone cancer	0.000242	0.00435	CcSEcCtD
Halofantrine—Chest pain—Epirubicin—bone cancer	0.000242	0.00435	CcSEcCtD
Halofantrine—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.000239	0.0353	CbGpPWpGaD
Halofantrine—Discomfort—Epirubicin—bone cancer	0.000239	0.0043	CcSEcCtD
Halofantrine—Malaise—Doxorubicin—bone cancer	0.000237	0.00426	CcSEcCtD
Halofantrine—Anorexia—Methotrexate—bone cancer	0.000237	0.00425	CcSEcCtD
Halofantrine—Confusional state—Epirubicin—bone cancer	0.000234	0.0042	CcSEcCtD
Halofantrine—Palpitations—Doxorubicin—bone cancer	0.000233	0.00418	CcSEcCtD
Halofantrine—Anaphylactic shock—Epirubicin—bone cancer	0.000232	0.00417	CcSEcCtD
Halofantrine—Cough—Doxorubicin—bone cancer	0.00023	0.00412	CcSEcCtD
Halofantrine—KCNH2—Hematopoietic Stem Cell Differentiation—IL3—bone cancer	0.000229	0.0338	CbGpPWpGaD
Halofantrine—Convulsion—Doxorubicin—bone cancer	0.000228	0.00409	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000226	0.00406	CcSEcCtD
Halofantrine—Arthralgia—Doxorubicin—bone cancer	0.000224	0.00402	CcSEcCtD
Halofantrine—Myalgia—Doxorubicin—bone cancer	0.000224	0.00402	CcSEcCtD
Halofantrine—Chest pain—Doxorubicin—bone cancer	0.000224	0.00402	CcSEcCtD
Halofantrine—Paraesthesia—Methotrexate—bone cancer	0.000223	0.004	CcSEcCtD
Halofantrine—Discomfort—Doxorubicin—bone cancer	0.000221	0.00398	CcSEcCtD
Halofantrine—Anorexia—Epirubicin—bone cancer	0.000221	0.00397	CcSEcCtD
Halofantrine—Dyspepsia—Methotrexate—bone cancer	0.000218	0.00392	CcSEcCtD
Halofantrine—Confusional state—Doxorubicin—bone cancer	0.000217	0.00389	CcSEcCtD
Halofantrine—Decreased appetite—Methotrexate—bone cancer	0.000216	0.00387	CcSEcCtD
Halofantrine—Anaphylactic shock—Doxorubicin—bone cancer	0.000215	0.00386	CcSEcCtD
Halofantrine—Fatigue—Methotrexate—bone cancer	0.000214	0.00384	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000212	0.0038	CcSEcCtD
Halofantrine—Paraesthesia—Epirubicin—bone cancer	0.000208	0.00374	CcSEcCtD
Halofantrine—Anorexia—Doxorubicin—bone cancer	0.000205	0.00368	CcSEcCtD
Halofantrine—Feeling abnormal—Methotrexate—bone cancer	0.000204	0.00367	CcSEcCtD
Halofantrine—Dyspepsia—Epirubicin—bone cancer	0.000204	0.00367	CcSEcCtD
Halofantrine—Gastrointestinal pain—Methotrexate—bone cancer	0.000203	0.00364	CcSEcCtD
Halofantrine—Decreased appetite—Epirubicin—bone cancer	0.000202	0.00362	CcSEcCtD
Halofantrine—Fatigue—Epirubicin—bone cancer	0.0002	0.00359	CcSEcCtD
Halofantrine—Constipation—Epirubicin—bone cancer	0.000199	0.00356	CcSEcCtD
Halofantrine—Urticaria—Methotrexate—bone cancer	0.000197	0.00354	CcSEcCtD
Halofantrine—Abdominal pain—Methotrexate—bone cancer	0.000196	0.00352	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000196	0.00351	CcSEcCtD
Halofantrine—Paraesthesia—Doxorubicin—bone cancer	0.000193	0.00346	CcSEcCtD
Halofantrine—Feeling abnormal—Epirubicin—bone cancer	0.000191	0.00343	CcSEcCtD
Halofantrine—Gastrointestinal pain—Epirubicin—bone cancer	0.00019	0.00341	CcSEcCtD
Halofantrine—Dyspepsia—Doxorubicin—bone cancer	0.000189	0.0034	CcSEcCtD
Halofantrine—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000187	0.0277	CbGpPWpGaD
Halofantrine—Decreased appetite—Doxorubicin—bone cancer	0.000187	0.00335	CcSEcCtD
Halofantrine—Fatigue—Doxorubicin—bone cancer	0.000185	0.00333	CcSEcCtD
Halofantrine—Urticaria—Epirubicin—bone cancer	0.000184	0.00331	CcSEcCtD
Halofantrine—Constipation—Doxorubicin—bone cancer	0.000184	0.0033	CcSEcCtD
Halofantrine—Abdominal pain—Epirubicin—bone cancer	0.000184	0.0033	CcSEcCtD
Halofantrine—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.00018	0.0266	CbGpPWpGaD
Halofantrine—Asthenia—Methotrexate—bone cancer	0.000178	0.0032	CcSEcCtD
Halofantrine—Feeling abnormal—Doxorubicin—bone cancer	0.000177	0.00318	CcSEcCtD
Halofantrine—Gastrointestinal pain—Doxorubicin—bone cancer	0.000176	0.00315	CcSEcCtD
Halofantrine—Pruritus—Methotrexate—bone cancer	0.000176	0.00315	CcSEcCtD
Halofantrine—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000173	0.0256	CbGpPWpGaD
Halofantrine—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000173	0.0256	CbGpPWpGaD
Halofantrine—Urticaria—Doxorubicin—bone cancer	0.000171	0.00306	CcSEcCtD
Halofantrine—Abdominal pain—Doxorubicin—bone cancer	0.00017	0.00305	CcSEcCtD
Halofantrine—Diarrhoea—Methotrexate—bone cancer	0.00017	0.00305	CcSEcCtD
Halofantrine—Asthenia—Epirubicin—bone cancer	0.000167	0.00299	CcSEcCtD
Halofantrine—Pruritus—Epirubicin—bone cancer	0.000164	0.00295	CcSEcCtD
Halofantrine—Dizziness—Methotrexate—bone cancer	0.000164	0.00295	CcSEcCtD
Halofantrine—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000163	0.0241	CbGpPWpGaD
Halofantrine—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.00016	0.0237	CbGpPWpGaD
Halofantrine—Diarrhoea—Epirubicin—bone cancer	0.000159	0.00285	CcSEcCtD
Halofantrine—Vomiting—Methotrexate—bone cancer	0.000158	0.00283	CcSEcCtD
Halofantrine—Rash—Methotrexate—bone cancer	0.000156	0.00281	CcSEcCtD
Halofantrine—Dermatitis—Methotrexate—bone cancer	0.000156	0.00281	CcSEcCtD
Halofantrine—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000156	0.023	CbGpPWpGaD
Halofantrine—Headache—Methotrexate—bone cancer	0.000155	0.00279	CcSEcCtD
Halofantrine—Asthenia—Doxorubicin—bone cancer	0.000154	0.00277	CcSEcCtD
Halofantrine—Dizziness—Epirubicin—bone cancer	0.000154	0.00276	CcSEcCtD
Halofantrine—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000153	0.0226	CbGpPWpGaD
Halofantrine—Pruritus—Doxorubicin—bone cancer	0.000152	0.00273	CcSEcCtD
Halofantrine—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.00015	0.0221	CbGpPWpGaD
Halofantrine—Vomiting—Epirubicin—bone cancer	0.000148	0.00265	CcSEcCtD
Halofantrine—Nausea—Methotrexate—bone cancer	0.000147	0.00265	CcSEcCtD
Halofantrine—Diarrhoea—Doxorubicin—bone cancer	0.000147	0.00264	CcSEcCtD
Halofantrine—Rash—Epirubicin—bone cancer	0.000146	0.00263	CcSEcCtD
Halofantrine—Dermatitis—Epirubicin—bone cancer	0.000146	0.00263	CcSEcCtD
Halofantrine—Headache—Epirubicin—bone cancer	0.000145	0.00261	CcSEcCtD
Halofantrine—Dizziness—Doxorubicin—bone cancer	0.000142	0.00255	CcSEcCtD
Halofantrine—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000139	0.0205	CbGpPWpGaD
Halofantrine—Nausea—Epirubicin—bone cancer	0.000138	0.00248	CcSEcCtD
Halofantrine—Vomiting—Doxorubicin—bone cancer	0.000137	0.00245	CcSEcCtD
Halofantrine—Rash—Doxorubicin—bone cancer	0.000135	0.00243	CcSEcCtD
Halofantrine—Dermatitis—Doxorubicin—bone cancer	0.000135	0.00243	CcSEcCtD
Halofantrine—Headache—Doxorubicin—bone cancer	0.000135	0.00242	CcSEcCtD
Halofantrine—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000128	0.0189	CbGpPWpGaD
Halofantrine—Nausea—Doxorubicin—bone cancer	0.000128	0.00229	CcSEcCtD
Halofantrine—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000124	0.0182	CbGpPWpGaD
Halofantrine—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000123	0.0182	CbGpPWpGaD
Halofantrine—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000114	0.0168	CbGpPWpGaD
Halofantrine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	9.37e-05	0.0138	CbGpPWpGaD
Halofantrine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	7.47e-05	0.011	CbGpPWpGaD
Halofantrine—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	7.46e-05	0.011	CbGpPWpGaD
Halofantrine—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	7.37e-05	0.0109	CbGpPWpGaD
Halofantrine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	6.47e-05	0.00956	CbGpPWpGaD
Halofantrine—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	6.39e-05	0.00943	CbGpPWpGaD
Halofantrine—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	6.06e-05	0.00894	CbGpPWpGaD
Halofantrine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	5.31e-05	0.00784	CbGpPWpGaD
Halofantrine—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	5.25e-05	0.00775	CbGpPWpGaD
Halofantrine—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	5.24e-05	0.00774	CbGpPWpGaD
Halofantrine—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	4.31e-05	0.00636	CbGpPWpGaD
Halofantrine—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	3.32e-05	0.0049	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—CYP3A4—bone cancer	3.22e-05	0.00475	CbGpPWpGaD
Halofantrine—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	3.17e-05	0.00469	CbGpPWpGaD
Halofantrine—KCNH2—SIDS Susceptibility Pathways—JUN—bone cancer	3.08e-05	0.00454	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—CYP3A4—bone cancer	2.79e-05	0.00411	CbGpPWpGaD
Halofantrine—CYP3A5—Biological oxidations—GSTP1—bone cancer	2.75e-05	0.00406	CbGpPWpGaD
Halofantrine—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	2.75e-05	0.00406	CbGpPWpGaD
Halofantrine—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	2.71e-05	0.00401	CbGpPWpGaD
Halofantrine—KCNH2—Neuronal System—BRAF—bone cancer	2.65e-05	0.00392	CbGpPWpGaD
Halofantrine—CYP2C8—Biological oxidations—GSTP1—bone cancer	2.38e-05	0.00352	CbGpPWpGaD
Halofantrine—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	2.35e-05	0.00347	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—CYP3A4—bone cancer	2.29e-05	0.00338	CbGpPWpGaD
Halofantrine—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	2.26e-05	0.00333	CbGpPWpGaD
Halofantrine—KCNH2—Neuronal System—MDM2—bone cancer	2.22e-05	0.00328	CbGpPWpGaD
Halofantrine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	1.97e-05	0.00292	CbGpPWpGaD
Halofantrine—CYP2D6—Biological oxidations—GSTP1—bone cancer	1.96e-05	0.00289	CbGpPWpGaD
Halofantrine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	1.93e-05	0.00285	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—NDUFA12—bone cancer	1.93e-05	0.00285	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—NDUFA12—bone cancer	1.67e-05	0.00247	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—NT5C3A—bone cancer	1.6e-05	0.00236	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—NT5C3A—bone cancer	1.38e-05	0.00204	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—NDUFA12—bone cancer	1.37e-05	0.00202	CbGpPWpGaD
Halofantrine—CYP3A4—Biological oxidations—GSTP1—bone cancer	1.28e-05	0.00189	CbGpPWpGaD
Halofantrine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	1.26e-05	0.00186	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—NT5C3A—bone cancer	1.14e-05	0.00168	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—NDUFA12—bone cancer	8.97e-06	0.00132	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—NT5C3A—bone cancer	7.43e-06	0.0011	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—ENO2—bone cancer	7e-06	0.00103	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—DHFR—bone cancer	6.49e-06	0.000959	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—GNA11—bone cancer	6.07e-06	0.000896	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—ENO2—bone cancer	6.06e-06	0.000895	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—DHFR—bone cancer	5.62e-06	0.00083	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—CYP3A4—bone cancer	5.5e-06	0.000812	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—GNA11—bone cancer	5.26e-06	0.000776	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—ENO2—bone cancer	4.98e-06	0.000735	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—CYP3A4—bone cancer	4.77e-06	0.000704	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.74e-06	0.0007	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—GSTP1—bone cancer	4.71e-06	0.000695	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—DHFR—bone cancer	4.62e-06	0.000682	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—GNA11—bone cancer	4.32e-06	0.000637	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—GSTP1—bone cancer	4.08e-06	0.000602	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—CYP3A4—bone cancer	3.91e-06	0.000578	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—GSTP1—bone cancer	3.35e-06	0.000494	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—ENO2—bone cancer	3.25e-06	0.000481	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—DHFR—bone cancer	3.02e-06	0.000446	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—GNA11—bone cancer	2.82e-06	0.000417	CbGpPWpGaD
Halofantrine—CYP3A5—Metabolism—PTGS2—bone cancer	2.44e-06	0.00036	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—GSTP1—bone cancer	2.19e-06	0.000323	CbGpPWpGaD
Halofantrine—CYP2C8—Metabolism—PTGS2—bone cancer	2.11e-06	0.000312	CbGpPWpGaD
Halofantrine—CYP2D6—Metabolism—PTGS2—bone cancer	1.73e-06	0.000256	CbGpPWpGaD
Halofantrine—CYP3A4—Metabolism—PTGS2—bone cancer	1.13e-06	0.000167	CbGpPWpGaD
